8-K: Reviva Pharmaceuticals Gains FDA Alignment on Phase 3 Program for Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals has secured FDA agreement on its Phase 3 clinical trial program for brilaroxazine in schizophrenia, potentially paving the way for a New Drug Application (NDA).

Summary

• Reviva Pharmaceuticals has received FDA alignment on its Phase 3 program for brilaroxazine in schizophrenia.
• The FDA has accepted the 4-week RECOVER-2 study for brilaroxazine.
• Two positive Phase 3 studies showing efficacy at week 4, along with 12-month long-term safety data, could support an NDA submission for acute schizophrenia treatment.
• A long-term randomized withdrawal study will be required post-approval to support maintenance of effect.
• The company plans to initiate the first clinical site for the RECOVER-2 trial in the second quarter of 2024.
• Topline data from the 1-year open-label extension (OLE) trial is expected in the fourth quarter of 2024.
• Reviva anticipates completing all NDA submission requirements by the third quarter of 2025.
• The RECOVER-2 trial is a global, randomized, double-blind, placebo-controlled study involving approximately 450 patients.
• Brilaroxazine will be administered at fixed doses of 30 mg or 50 mg once daily for 28 days.
• The primary endpoint is a decrease in the Positive and Negative Symptoms Assessment total score compared to placebo at day 28.

Sentiment

Score: 8

Explanation: The document is positive due to the FDA alignment and clear path to NDA submission, but there are still risks associated with clinical trials and regulatory approval.

Positives

• The FDA's acceptance of the 4-week RECOVER-2 study is a significant step forward for brilaroxazine.
• The FDA's indication that two positive Phase 3 studies with long-term safety data could support an NDA is a clear path to potential approval.
• The company has already completed a pivotal Phase 3 trial (RECOVER-1) with positive results.
• The planned initiation of the RECOVER-2 trial in Q2 2024 demonstrates progress.
• The expected topline data from the 1-year OLE trial in Q4 2024 provides a near-term milestone.
• The company's timeline to complete NDA requirements by Q3 2025 is well-defined.

Negatives

• A long-term randomized withdrawal study is required post-approval, adding to the regulatory burden.
• The company is still in the clinical trial phase, and there is no guarantee of success.
• The company is reliant on the success of the RECOVER-2 trial and the OLE trial.

Risks

• The success of the RECOVER-2 trial is crucial for NDA submission, and failure could significantly impact the company.
• Clinical trials are subject to risks, including patient enrollment, data variability, and unexpected adverse events.
• Regulatory approval is not guaranteed, and the FDA may require additional studies or data.
• The company's ability to raise sufficient funding to complete the trials and commercialize the drug is a risk.
• Competition from other pharmaceutical companies developing treatments for schizophrenia is a risk.

Future Outlook

The company anticipates completing all NDA submission requirements by the third quarter of 2025, contingent on successful clinical trial outcomes. They also plan to explore brilaroxazine for other neuropsychiatric indications.

Management Comments

• Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, stated that they are pleased to receive positive feedback from the FDA and acceptance of a 4-week registrational study for their brilaroxazine program.
• The CEO also noted that the FDA clarified that their NDA submission could include two 4-week phase 3 studies showing efficacy and a 12-month long-term safety study.

Industry Context

This announcement is significant in the context of the pharmaceutical industry's ongoing efforts to develop more effective treatments for schizophrenia, a condition with significant unmet medical needs. The alignment with the FDA provides a clear regulatory pathway for Reviva's brilaroxazine, potentially positioning it as a competitor in the market.

Comparison to Industry Standards

• The requirement of two positive Phase 3 trials with 4-week efficacy data and 12-month safety data is consistent with industry standards for NDA submissions for psychiatric drugs.
• The use of a randomized, double-blind, placebo-controlled design for the RECOVER-2 trial is a standard approach in clinical trials for schizophrenia.
• The inclusion of key secondary endpoints such as CGI severity, social functioning, and cognition is also in line with industry best practices for assessing the efficacy of schizophrenia treatments.
• Companies like Alkermes (ALKS) with their drug Aristada, and Intra-Cellular Therapies (ITCI) with Caplyta, have also gone through similar regulatory pathways for their schizophrenia treatments, making Reviva's approach comparable to established players in the market.

Stakeholder Impact

• Shareholders will likely view the FDA alignment positively, potentially increasing the company's stock value.
• Patients with schizophrenia may benefit from a new treatment option if brilaroxazine is approved.
• Employees of Reviva will be involved in the execution of the clinical trials and regulatory submissions.
• The company's success could lead to partnerships and collaborations with other pharmaceutical companies.

Next Steps

• Initiate the first clinical site in the RECOVER-2 trial during Q2 2024.
• Complete the RECOVER-2 trial.
• Complete the 1-year open-label extension (OLE) trial.
• Submit an NDA for brilaroxazine in schizophrenia by Q3 2025.

Key Dates

Keywords

brilaroxazine, schizophrenia, FDA, Phase 3, clinical trial, NDA, RECOVER-2, drug development, CNS, pharmaceutical